Rapid Identification of Antibodies with Efficacy against Omicron SARS-CoV-2 Variants

All Resources

Paper Summary

In a paper published in Cell Reports, researchers used Bruker Cellular Analysis’ Beacon® system to show that vaccination against SARS-CoV-2 can yield antibodies with efficacy against other or yet-unknown viral variants.

First Name*

Last Name*

Email*

Company Name*

Country*

Application Area*

Research Area*

By submitting this form, I confirm that I would like to receive information from Bruker Cellular Analysis and I agree to the Website Privacy Policy and Terms of Conditions.*

What's Inside

In this Paper Summary we discuss:

Keeping pace with the COVID-19 pandemic.

Optofluidics-powered screening.

Demonstrating in vivo efficacy against Omicron variants.

A Deeper Look

More about this Paper Summary

Accelerating Future Discoveries

With the aid of Bruker Cellular Analysis’ technology, Hastie and her team demonstrated that vaccination induced individuals to produce antibodies with broad utility and therapeutic protection—even against viruses that had not yet evolved at the time of vaccination.

Download this paper summary to learn more!

Get the Paper Summary

Back to the Top